Repository logo
 
Publication

Drug-drug interactions and risk factors of interactions in oncology

dc.contributor.authorFernandes, Sara
dc.contributor.authorTeixeira, S.
dc.contributor.authorFerraz Oliveira, Rita
dc.date.accessioned2024-09-17T13:02:43Z
dc.date.available2024-09-17T13:02:43Z
dc.date.issued2014-04
dc.description.abstractDrug-Drug interactions (DDI’s) are a frequent occurrence in clinical practice and in particular in oncology. Cancer patients are assumed as a risk group, mainly due to the high number of drugs related, as well as the changes inherent in the cancer context. In the context of cancer, the studies on DDI's in oncology are reduced in number, presenting incidences ranging from 12% to 63%, depending on the type of population study. Following the high morbidity and mortality that can be associated with DDI's, there is a need to conduct further study on this topic, in order to minimize the occurrence of dangerous DDI's and ensure the prescription and administration of effective and secure therapeutics. Identify and characterize the most commons DDI’s and identify possible risk factors involved in the occurrence of DDI's, in oncology. It was performed a literature review of articles published in several electronic databases (Pubmed, Ebsco and B-on), about DDI’s in the context of cancer patients, from the year 2005. After analysis of the articles obtained were considered seven articles, six articles on the occurrence of potential DDI’s and one study on the occurrence of real DDI’s, in oncology. It should be noted the reduced percentage of studies on real DDI's, where was verified that about 2% of the patients studied were exposed to DDI's. As regards to the potential DDI's, it is noteworthy the high number of DDI's detected and the high percentage of cancer patients exposed, both ambulatory context as in internment (about one-third of subjects in study). Regardless of the type of cancer patient studied, the drugs most referenced are anticonvulsant, antihypertensive and warfarin. The interactions detected were mainly pharmacokinetics and of moderate severity. As regards to risk factors were identified the age, the presence of comorbidities and the polypharmacy, the latter being described as the main factor for the occurrence of DDI's. In short, it was verified that DDI's in oncology require special attention, so the implementation of strategies allowing precocious detection are essential or even avoiding its occurrence. Besides clinical issues involved, DDI’s are associated to a major economic impact, so their complication becomes a higher cost to this patient’s treatment. The health professional is an essential agent preventing DDI's, to ensure the effectiveness of therapy and quality of life of patients.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFernandes, S., Teixeira, S., & Oliveira, R. (2014). Drug-drug interactions and risk factors of interactions in oncology. Livro de Atas do X Colóquio de Farmácia / 10th Pharmacy Colloquium – Proceedings Book, 46/47.pt_PT
dc.identifier.isbn978-989-97801-2-5
dc.identifier.urihttp://hdl.handle.net/10400.22/26009
dc.language.isoporpt_PT
dc.publisherÁrea Técnico-Científica de Farmácia - Escola Superior de Tecnologia da Saúde do Portopt_PT
dc.relation.publisherversionhttps://recipp.ipp.pt/bitstream/10400.22/4941/1/L_AgostinhoCruz_2014.pdfpt_PT
dc.subjectDrug-Drug Interactionspt_PT
dc.subjectOncologypt_PT
dc.titleDrug-drug interactions and risk factors of interactions in oncologypt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlacePortopt_PT
oaire.citation.endPage47pt_PT
oaire.citation.startPage46pt_PT
oaire.citation.titleLivro de Atas do X Colóquio de Farmácia / 10th Pharmacy Colloquium – Proceedings Bookpt_PT
person.familyNameFernandes
person.familyNameFerraz Oliveira
person.givenNameSara
person.givenNameRita
person.identifier.ciencia-id1C12-D800-38A4
person.identifier.ciencia-idFD1F-2E0C-1254
person.identifier.orcid0000-0001-7042-1941
person.identifier.orcid0000-0003-3933-5740
person.identifier.scopus-author-id57203278917
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT
relation.isAuthorOfPublication6c2ed5f0-c3fd-4559-99a3-b8d78d019b47
relation.isAuthorOfPublication6c1b7213-1303-47eb-bfa7-ecbef6a9b8d9
relation.isAuthorOfPublication.latestForDiscovery6c2ed5f0-c3fd-4559-99a3-b8d78d019b47

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
COM_Sara Fernandes 1.pdf
Size:
821.29 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: